argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer. By translating immunology breakthroughs into innovative drug candidates, argenx is building a world-class portfolio of first-in-class antibodies in both early and late clinical-stages of development.

argenx is evaluating its lead candidate, efgartigimod, in multiple serious autoimmune indications and cusatuzumab in hematological malignancies in collaboration with Janssen, along with advancing earlier stage assets within its therapeutic franchises.

Stock Information

$ 279.22
-1.05 %
Volume: 163237
Last: 01/18/2021 17:35
€ 231.20
-0.09 %
Volume: 22031
Last: 01/18/2021 17:35

Press Releases

Press releases pertaining to argenx stock, financial information and investments.